Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 19;17:194. doi: 10.1186/s12974-020-01870-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 4 — Lentiviral vector-mediated overexpression of miR-669c decreases ischemic brain damage and ameliorates neurological deficits. Quantification (a) and representative T2-weighted MRI brain images of tMCAo mice injected either with control LV1-GFP (b) or LV1-miR-669c (c) at 1 dpi. Respectively, panels d-f depict the quantification (d) and representative MRI images of control LV1-GFP (e) or LV1-miR-669c (f) animals 3 dpi. Unpaired two-tailed t tests: *p < 0.05, **p < 0.01 compared to LV1-GFP tMCAo mice. N = 9-11 in each tMCAo group. TMCAo animals intrastriatally injected with LV1-miR-669c (669) showed improved locomotor functions at 1 (g) and 3 dpi (h). Behavior was evaluated by composite neuroscore testing. One-way ANOVA followed by Bonferroni’s post hoc tests: *p < 0.05, ***p < 0.001 compared to sham-operated animals and ^#p < 0.05, ^##p < 0.01 compared to LV1-GFP tMCAo mice. N = 11 in sham-operated groups and N = 17-18 for tMCAo groups. Panels i-n illustrate the extent of miR-669c-3p expression (red) and Iba1 immunoreactivity (magenta) in representative LV1-GFP (i, k, m) or LV1-miR-669c (j, l,n) injected sham animals at 3 dpi. The LV injection sites are marked with white dotted lines